Qutenza (Neuropathic Pain) - Forecast and Market Analysis to 2022
Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability.
Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/qutenza-neuropathic-pain-forecast-and-market-analysis-to-2022
New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.
Qutenza (capsaicin 8% patch) was developed by NeurogesX, and is the first and only prescription-strength capsaicin treatment. It was approved in Europe (where is it marketed under license to Astellas Pharma) in March 2009 for the treatment of peripheral NP in non-diabetic adults, both as a monotherapy and in combination with other products. In the US, Qutenza was approved by the FDA in November 2009 for the treatment of PHN. NeurogesX retained the full commercial rights to Qutenza in the US and worldwide (outside Europe).
Download Full Report with TOC:...